Comparing 7-day and 14-day doxycycline treatment for multiple erythema migrans
Official title: Duration of Doxycycline Treatment in Patients With Multiple Erythema Migrans (MEM). A Randomized Clinical Trial
Run by University Medical Centre Ljubljana · NCT03337932 · Data updated 2026-11-12
This study is testing whether a 7-day or a 14-day course of doxycycline works better for people with multiple erythema migrans.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 200 (estimated) |
| Sponsor | University Medical Centre Ljubljana Academic / other |
| Locations | 1 site (Ljubljana) |
| Status | Recruiting |
| Started | May 1, 2018 |
| Main results expected | December 31, 2027 |
| Study ends | December 31, 2027 |
| Registry record updated | April 29, 2026 |
| Trial ID | NCT03337932 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are individuals diagnosed with multiple erythema migrans.
✕Probably not a fit
Patients who are pregnant, lactating, immunocompromised, or have serious adverse reactions to doxycycline will not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study aims to evaluate the effectiveness of two different durations of doxycycline treatment, specifically 7 days versus 14 days, in patients diagnosed with multiple erythema migrans. Participants will receive doxycycline 100 mg orally twice daily for the assigned duration, while controls will not have a history of Lyme disease. The goal is to determine which treatment duration is more effective in managing this condition.
Why it matters
Potential benefit: If successful, this study could provide clearer guidelines for the optimal duration of doxycycline treatment, improving patient outcomes in managing erythema migrans.
How similar studies have gone: While there have been studies on doxycycline for Lyme disease, this specific comparison of treatment duration is relatively novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: • multiple erythema migrans Exclusion Criteria: * pregnancy or lactation * immunocompromised * serious adverse event to doxycycline * taking antibiotic with antiborrelial activity within 10 days * extracutaneous manifestations of lyme borreliosis
Where it's running
-
University Medical center Ljubljana
Ljubljana, Slovenia Recruiting
Study contacts
- Principal investigator: Daša Stupica, MD PhD — University Medical Centre Ljubljana
- Study coordinator: Daša Stupica, MD, PhD
- Email: dasa.stupica@kclj.si
- Phone: +386 31 689 324
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Lidocaine Infiltration to See If It Helps Inflammation and Brain Function After Head and Neck Cancer Surgery
This study tests whether different amounts of lidocaine injected into the surgical area can influence inflammation and brain-related outcomes after major head and neck cancer surgery in adults.
-
Minimal Sedation After Out-of-Hospital Cardiac Arrest
This study tests whether stopping continuous sedation right after return of circulation is as safe as keeping patients sedated in the early hours after OHCA.
-
Empagliflozin, Metformin, or both for muscle energy in adults with type 2 diabetes
This study tests whether empagliflozin, metformin, or their combination can improve skeletal muscle oxidative capacity and microvascular reactivity in adults recently diagnosed with type 2 diabetes.
-
Predicting pancreatogenic diabetes after partial pancreas removal
Aims to see if clinical, lab, imaging, and tissue findings before and after partial pancreas surgery can predict who will develop pancreatogenic diabetes.
-
Dexamethasone for tick-borne encephalitis
This trial will see if dexamethasone helps adults with confirmed tick-borne encephalitis who have meningitis, encephalitis, or meningomyelitis.
-
Dual PCSK9 Inhibition in secondary prevention for high LDL-C with statin intolerance
This study tests whether combining inclisiran and alirocumab lowers LDL cholesterol better than either drug alone in people with ASCVD who can’t tolerate statins.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.